Latest Group B streptococcal infection Stories
A more rapid laboratory test for pregnant women to detect potentially deadly Group B strep (GBS) has been successful at identifying GBS colonization in six and a half hours, according to the results of a study from The University of Texas Health Science Center at Houston (UTHealth). The more rapid test could be helpful for the 13 percent of patients who experience pre-term labor before they are screened for GBS, which usually occurs between 35 and 37 weeks of gestation. The current...
HUBBARD, Ohio, Aug. 1, 2012 /PRNewswire/ -- NanoLogix (OTC Markets: NNLX), a biotechnology innovator in the rapid detection and identification of live-threat bacteria, is featured today in the USA Today Group B Strep (GBS) Awareness Campaign titled Your guide to Group B Strep. The campaign featured in the USA Today News Section promotes public education on the dangers of GBS in newborns and highlights the latest testing methods to help prevent the disease. Research using...
A more accurate, faster diagnostic test for Group B Streptococcal infection in babies has been reported in the Journal of Medical Microbiology. The new test could allow better treatment and management of the disease and reduce the risk of mortality among newborns. Group B streptococcus (GBS) infections, caused by the bacterium Streptococcus agalactiae, are the most common cause of meningitis, septicaemia and pneumonia in newborns. In 2010 there were 506 cases of GBS infections in infants...
CAMBRIDGE, Mass., May 15, 2012 /PRNewswire/ -- IntelligentMDx (IMDx) announced today that it has obtained CE-marking for a new automated, high-throughput, qualitative in vitro diagnostic test designed for the rapid detection of Group B Streptococcus (GBS) for use in screening pregnant women and those in labor who may be infected with the pathogen. GBS is responsible for life-threatening bacterial infections in newborns, including sepsis, meningitis, and pneumonia. The IMDx(TM) GBS for...
BALTIMORE, March 28, 2012 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX) announced today the U.S. Food and Drug Administration (FDA) clearance of the BD MAX(TM) Group B Streptococcus (GBS) Assay and Clinical Laboratory Improvement Amendments (CLIA) moderate complexity test categorization on the second-generation BD MAX(TM) System. The BD MAX GBS Assay is an in vitro diagnostic (IVD) test for detection of GBS DNA in Lim Broth cultures - enabling laboratories to...
(Ivanhoe Newswire) -- Bloodstream infections in newborns can lead to serious complications with substantial morbidity and mortality. What's more, the pathogens responsible for neonatal infections have changed over time. In recent years, however, antibiotic prophylaxis given to at-risk mothers has reduced the incidence of early-onset group B streptococcal infections among their babies.A new study aimed at determining current early-onset sepsis rates among newborns, the pathogens involved, and...
Bloodstream infections in newborns can lead to serious complications with substantial morbidity and mortality. What's more, the pathogens responsible for neonatal infections have changed over time. In recent years, however, antibiotic prophylaxis given to at-risk mothers has reduced the incidence of early-onset group B streptococcal infections among their babies.A new nationwide, multi-site study aimed at determining current early-onset sepsis rates among newborns, the pathogens involved, and...
In a study to be presented today at the Society for Maternal-Fetal Medicine's (SMFM) annual meeting, The Pregnancy Meeting â„¢, in San Francisco, researchers will present findings that show that many women are having different test results for Group B streptococcus (GBS) between their routine third trimester screening and a rapid test performed at the time of labor.GBS early-onset sepsis is a leading cause of neonatal infection. GBS is a bacterium that normally exists in the genital...
BALTIMORE, Aug. 3 /PRNewswire-FirstCall/ -- BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), announced today that it has received "Moderate Complexity" status from the U.S. Food and Drug Administration, under the Clinical Laboratory Improvement Amendments (CLIA), for the BD MAX(TM) GBS Assay for Group B Streptococcus (GBS) on the BD MAX(TM) System. With the "Moderate Complexity" categorization, the BD MAX GBS Assay will increase access to cost effective...
BALTIMORE, June 2 /PRNewswire-FirstCall/ -- BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration to market the BD MAX(TM) GBS Assay for Group B Streptococcus (GBS) on the BD MAX(TM) System. The BD MAX System is a next-generation automated workstation for molecular testing designed to streamline workflow and offer full walkaway automation to accommodate varying workloads...
